Shili Duan
Overview
Explore the profile of Shili Duan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1606
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yadav M, Harding R, Li T, Xu X, Gall-Duncan T, Khan M, et al.
Sci Adv
. 2024 Jul;
10(29):eado5264.
PMID: 39028820
Huntingtin protein, mutated in Huntington's disease, is implicated in nucleic acid-mediated processes, yet the evidence for direct huntingtin-nucleic acid interaction is limited. Here, we show wild-type and mutant huntingtin copurify...
2.
Nie D, Tabor J, Li J, Kutera M, St-Germain J, Hanley R, et al.
Nat Chem Biol
. 2024 Jul;
20(12):1597-1607.
PMID: 38965384
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins...
3.
Nie D, Tabor J, Li J, Kutera M, St-Germain J, Hanley R, et al.
bioRxiv
. 2023 Nov;
PMID: 37961297
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins...
4.
Wu Q, Nie D, Ba-Alawi W, Ji Y, Zhang Z, Cruickshank J, et al.
Nat Chem Biol
. 2022 May;
18(8):821-830.
PMID: 35578032
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and few effective therapies. Here we identified MS023, an inhibitor of type I protein arginine...
5.
Wei Y, Redel C, Ahlner A, Lemak A, Johansson-Akhe I, Houliston S, et al.
Nucleic Acids Res
. 2022 Mar;
50(6):3505-3522.
PMID: 35244724
Despite MYC dysregulation in most human cancers, strategies to target this potent oncogenic driver remain an urgent unmet need. Recent evidence shows the PP1 phosphatase and its regulatory subunit PNUTS...
6.
Patel P, Abraham K, Guturi K, Halaby M, Khan Z, Palomero L, et al.
J Clin Invest
. 2021 Feb;
131(3).
PMID: 33529165
Germline mutations in BRCA1 and BRCA2 (BRCA1/2) genes considerably increase breast and ovarian cancer risk. Given that tumors with these mutations have elevated genomic instability, they exhibit relative vulnerability to...
7.
Wu Q, Ba-Alawi W, Deblois G, Cruickshank J, Duan S, Lima-Fernandes E, et al.
Nat Commun
. 2020 Aug;
11(1):4205.
PMID: 32826891
Triple negative breast cancer (TNBC) is a deadly form of breast cancer due to the development of resistance to chemotherapy affecting over 30% of patients. New therapeutics and companion biomarkers...
8.
Tauber M, Kreuz S, Lemak A, Mandal P, Yerkesh Z, Veluchamy A, et al.
Nucleic Acids Res
. 2020 Jul;
48(14):7728-7747.
PMID: 32609811
UHRF1 is an important epigenetic regulator associated with apoptosis and tumour development. It is a multidomain protein that integrates readout of different histone modification states and DNA methylation with enzymatic...
9.
Kaustov L, Lemak A, Wu H, Faini M, Fan L, Fang X, et al.
Nucleic Acids Res
. 2019 Aug;
47(17):9433-9447.
PMID: 31400120
Histone H3K4 methylation is an epigenetic mark associated with actively transcribed genes. This modification is catalyzed by the mixed lineage leukaemia (MLL) family of histone methyltransferases including MLL1, MLL2, MLL3,...
10.
Wu Q, Heidenreich D, Zhou S, Ackloo S, Kramer A, Nakka K, et al.
Nat Commun
. 2019 Apr;
10(1):1915.
PMID: 31015424
Bromodomains (BRDs) are conserved protein interaction modules which recognize (read) acetyl-lysine modifications, however their role(s) in regulating cellular states and their potential as targets for the development of targeted treatment...